Gilead Sciences (GILD) PT Lowered to $122 at RBC Capital
Tweet
Share
E-mailGet Alerts GILD Hot Sheet
Price: $125.71 +0.67%
Rating Summary:
36 Buy, 7 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 4 | Down: 13 | New: 23
Rating Summary:
36 Buy, 7 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 4 | Down: 13 | New: 23
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Gilead Sciences (NASDAQ: GILD) to $122.00 (from $123.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- EU approves Gilead's Trodelvy for first-line metastatic TNBC
- Take-Two Interactive (TTWO) PT Raised to $368 at BofA Securities
- Globe Life (GL) PT Raised to $215 at TD Cowen
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
